Shares of Biogen Inc. BIIB slipped 1.40% to $138.37 Friday, on what proved to be an all-around rough trading session for the ...
Biogen Inc. closed 41.53% short of its 52-week high of $238.00, which the company achieved on July 12th.
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared ...
I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America. Thank you very much for joining us. Well ...
From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...
The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...
In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer’s disease, according to the federal … ...
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $135.00. The company’s shares closed yesterday ...
“Under the theme “Designing Future Society for Our Lives,” the Expo will address eight key thematic areas focused on global challenges, providing an exceptional platform for PNG to showcase its trade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
